CIZZLE BIOTECHNOLOGY HOLDINGS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.7 GBX | 0.00% |
|
+3.03% | -12.82% |
| Apr. 30 | EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down | AN |
| Apr. 30 | Cizzle Biotechnology Holdings Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | - | Capitalization | 7.09M 8.88M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 | Net income 2023 | -1M -1.25M | EV / Sales 2022 | - |
| Net cash position 2022 | 478K 599K | Net cash position 2023 | 1.56M 1.95M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-4.63
x | P/E ratio 2023 |
-3.9
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 61.98% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +3.03% | ||
| Current month | +3.03% | ||
| 1 month | -5.56% | ||
| 3 months | -26.09% | ||
| 6 months | -8.11% | ||
| Current year | -12.82% |
1 week
1.57
1.80
1 month
1.571.84
Current year
1.573.38
1 year
1.573.70
3 years
1.3013.00
5 years
1.3013.00
10 years
1.3013.00
| Managers | Title | Age | Since |
|---|---|---|---|
Nigel Lee
DFI | Director of Finance/CFO | 63 | 21-05-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dawn Coverley
BRD | Director/Board Member | 59 | 21-05-13 |
Nigel Lee
DFI | Director of Finance/CFO | 63 | 21-05-13 |
John Treacy
BRD | Director/Board Member | 42 | 19-01-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1.7 | 0.00% | 132,912 |
| 24-05-09 | 1.7 | 0.00% | 1,422,919 |
| 24-05-08 | 1.7 | 0.00% | 1,414,576 |
| 24-05-07 | 1.7 | +3.03% | 3,141,529 |
| 24-05-03 | 1.65 | 0.00% | 226,509 |
Delayed Quote London S.E., May 10, 2024 at 11:35 am EDT
More quotes
Cizzle Biotechnology Holdings Plc is a United Kingdom-based diagnostics development company. The Company is engaged in the development of a blood test for the early detection of lung cancer. Its prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. Its prototype confirmative test has been developed to address the false positive rates of computed tomography (CT) scanning. The test is intended to address a clear unmet clinical need, which is early detection of lung cancer, when curative surgical resection is possible.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.82% | 8.43M | |
| +17.96% | 44.96B | |
| +48.77% | 41.85B | |
| +1.17% | 42.65B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- PSL Stock
